Reply by Authors
J Urol
.
2021 May;205(5):1371.
doi: 10.1097/JU.0000000000001568.02.
Epub 2021 Mar 11.
Authors
Andrew J Armstrong
1
,
Neal D Shore
2
,
Russell Z Szmulewitz
3
,
Daniel P Petrylak
4
,
Jeffrey Holzbeierlein
5
,
Arnauld Villers
6
,
Arun Azad
7
,
Antonio Alcaraz
8
,
Boris Alekseev
9
,
Taro Iguchi
10
,
Francisco Gomez-Veiga
11
,
Brad Rosbrook
12
,
Ho-Jin Lee
13
,
Gabriel P Haas
13
,
Arnulf Stenzl
14
Affiliations
1
Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, North Carolina.
2
Carolina Urologic Research Center, Myrtle Beach, South Carolina.
3
The University of Chicago, Chicago, Illinois.
4
Yale Cancer Center, New Haven, Connecticut.
5
The University of Kansas Medical Center, Kansas City, Kansas.
6
University Hospital Centre, Lille University, Lille, France.
7
Monash Health, Melbourne, Victoria, Australia.
8
Hospital Clinic de Barcelona, Barcelona, Spain.
9
Hertzen Moscow Cancer Research Institute, Moscow, Russia.
10
Osaka City University Graduate School of Medicine, Osaka, Japan.
11
Hospital Universitario de Salamanca, GITUR-IBSAL, Salamanca, Spain.
12
Pfizer Inc. , San Diego, California.
13
Astellas Pharma Inc., Northbrook, Illinois.
14
University Hospital, Eberhard Karls University of Tübingen, Tübingen, Germany.
PMID:
33705222
DOI:
10.1097/JU.0000000000001568.02
No abstract available
Publication types
Comment